

Estriol 1mg - Estradiol 1mg (Biest 2mg/g (50:50))- Progesterone 40mg - Testosterone 2.5mg/g Cream (Phytobase®)(BUD Study)

Total Formula Quantity

100 grams

Ingredients

Quantity

Estriol 10 mg/g (1%) Cream (Phytobase)	10 grams	
Estradiol 10 mg/g (1%) Cream (Phytobase)	10 grams	
Progesterone USP Micronized	4 grams	
Testosterone USP Micronized	0.25 grams	
Diethylene Glycol Monoethyl Ether NF	4 grams	4.04 milliliters
Phytobase™	71.75 grams	

Ingredient Disclaimer

The density of Diethylene Glycol Monoethyl Ether is 0.991 g/mL

This formulation contains ingredient(s) that are on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. Follow all relevant USP <800> guidelines when handling, storing, and compounding with this material.

Subformula

FA-23760

FA-23761

Method/Instructions

1. Calculate amount of ingredients needed.
2. Accurately weigh and measure each ingredient.
3. Combine Estriol and Estradiol 10mg/g (1%) Dilutions and powders with Diethylene Glycol Monoethyl Ether with thorough mixing.
4. Add enough Phytobase™ Cream to Step #3 to bring to final volume then mix in an appropriate size FagronLab EMP jar for 3-4 minutes at a medium mix speed.
5. Process through Three Roll/Ointment Mill as needed.
6. Mix compound again for 1 minute at a low mix speed, or by hand, and package in Topi-Click (polypropylene) dispensing device

Formulation Notes

- For optimal results this formulation should be compounded using mechanical mixing devices that ensure thorough mixing and produce high shearing forces (electronic mortar & pestle combined with processing through an ointment mill).

Equipment

FagronLab EMP

Supplies/Dispensers

Topi-Click

PPE Notes

Refer to USP <800> current guidelines for specific minimum garbing requirements. Gowns, head, hair, shoe covers, and two pairs of chemotherapy gloves are required for compounding sterile and nonsterile HDs. Refer to current USP <800> and USP <795> or USP <797> guidelines as well as the facility's SOPs for additional information on personal protective equipment (PPE) for non-sterile and sterile hazardous compounding.

Refer to USP <795> current guidelines for specific minimum garbing requirements. Gloves must be worn for all compounding activities. Additional garb may be necessary depending on the type of compounding performed and per the facility's SOP.

Storage

Controlled Room Temperature 20 to 25 °C

Protect from light

Store in a tightly closed container

BUD

180 days per study

AUX

This medication was specially compounded in our pharmacy for you at the direction of your prescriber.



References

1. Taylor S, Haselhorst R. Extended chemical and microbial stability of various hormones in Phytobase and HRT Heavy Cream Bases. Int J Pharm Compd. 2024; 28(4): 344-350.
2. Hormone Stability Studies. Document Updated February 2025
3. The ESTIMATED BEYOND-USE DATE is a physical stability estimate based on information from published references, medical and scientific literature, observed organoleptic stability, formulator practical experience and current USP guidelines. Please refer to USP Chapter <795> for additional information regarding appropriate Beyond-Use determination.



QC check section

Describe the appearance of the finished compound (color, odor, etc):

Compounded Active Pharmaceutical Ingredients match the original prescription document: Yes / No

Describe the closure container used for finished compound (Topiclick, etc.):

Quality control measures taken and results (pH measurements ,etc):

Visual inspection of compound within expectations: Yes / No

Container closure checked for and free of any leakage and/or cracks: Yes / No

Compounded preparation released for dispensing by (name):

 Disclaimer

This example compounding formulation ("Example Formula") is being provided by Fagron Academy upon the request of Customer and is being provided for informational purposes only. Fagron Academy, its owners, officers, agents, affiliates and employees make no representation or warranty whatsoever with respect to this Example Formula. Customer is responsible for and, by its receipt of the Example Formula, agrees it will take any and all steps necessary to independently verify any formulation, concentrations, and raw amounts of components provided in this Example Formula, including any formulation that is the same or similar to the Example Formula, that is used in Customer's business to ensure the accuracy of all product components and component concentrations, as well as the compatibility and stability of all formulation components. In consideration of being provided the Example Formula, Customer understands and agrees that Fagron Academy, its owners, officers, agents, affiliates and employees shall not be responsible for any claims, actions, liabilities, losses, expenses, damages, judgment or costs arising directly or indirectly or related in any way to any actual or alleged injury to any person (including death) or any damage to any tangible property resulting or claimed to result wholly or in part from any formulation that is the same or similar to any Example Formula.

Date last modified
01/22/2026